individuals suffer from neurological
disorders, with dementia being the world’s 7th most frequent cause of death.
leading global cause of disability is mental health problems. Brain health is the foundation of our mental health.
FDA final marketing approval rate for central nervous system (CNS) drugs, compared to 13.3% for non-CNS drugs.
“ViewMind’s technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition. ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.
The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment.”
ViewMind detects neuropsychiatric and neurodegenerative diseases based on the data and generates a presumptive diagnostic report for the clinician.
Founder and Managing Partner of R3i Ventures, a seed-stage VC Fund based in Luxembourg, Singapore and Silicon Valley.
Founder and managing partner of CITES, a deeptech early stage VC fund.
Professor, Director and founder of the Antioquia Neuroscience Group at the University of Antioquia in Medellín, Colombia. Dr. Lopera is one of the world’s leading specialists on Alzheimer’s & neurodegenerative disorders.
Dr. Greenleaf is a Stanford University research neuroscientist and medical product developer and one the world’s leading authorities in the use of virtual reality technology in healthcare.
A pharmaceutical executive with over 20 years of experience in global medical roles, including Novo Nordisk, AstraZeneca and Zealand Pharma.